1. Pune-based Gennova Biopharmaceuticals secures US$ 13.38 Million funding to develop Nipah virus vaccine.
2. LUPIN Company has acquired UK-based Renascience Pharma for US$15.42 Million(12.3 Million British Pounds).
3. Indian drug maker Granules completes acquisition of CDMO Senn Chemicals AG for US$22.68 Million(Swiss Franc CHF 20 Million).
4. Intas Pharmaceuticals, through its US division Accord BioPharma, acquired Udenyca Biosimilar business from Coherus BioSciences, in deal valued at up to US$558.4 Million.
5. Zydus owned Zynext Ventures Invests in Feldan Therapeutics on their novel Feldan Shuttle platform.
6. Zydus MedTech has obtained commercial rights to an aortic valve device from Brazil-based Braile Biomedica for Europe, India, and other select markets.
7. Dr Reddy's In-licenses exclusive rights from Sanofi to promote and distribute Beyfortus in India.
8. Tempus AI has signed a three-way deal with AstraZeneca and Pathos AI to construct a data-based oncology model that could ultimately be used to develop new cancer drugs. Tempus is set to receive US$200 Million in data licensing and model development fees.
9. Teladoc buys virtual therapy startup UpLift for US$30 Million.
10. Esteve has signed a license and supply agreement with Eton Pharmaceuticals for global rights to Increlex (mecasermin), except for USA, paying an upfront of US$4.3 Million(4 million euros).
11. Repertoire® Immune Medicines Enters into Collaboration and License Agreement with Genentech for the Development of T cell-Targeted Therapies for an Autoimmune Disease.
12. Veraxa Biotech has signed a merger agreement with Voyager Acquisition, a special purpose acquisition company (SPAC) listed on NASDAQ, to form a publicly traded biopharmaceutical company focused on novel cancer therapies.
13. Siemens and Miko Pharma sign generics manufacturing deal.
Aagami Updates:
1. Aagami to attend BIO International Convention in Boston (June 16-19).The partnering system is now open. Please send us your meeting requests soon.
2. California based Mountain View Pharma (MVP) has awarded yet another contract extension to Aagami for helping them to sell their PharmaPEG Technology IP, Data package, NOL and the company.
3. New Client Win: Massachusetts based Clinical stage company focused on rare disease. The mandate is to assist the client for possible sale, disposition or equity or assets/Licensing/Co-development agreements.
4. New Assignment: U.S.-based medtech client revolutionizing medical imaging with the world’s first portable, single-sided MRI platform (On the market). With over US $60 Million raised, here is a lucrative investment opportunity to invest in current B-4/B-5 round at special terms.
Select Partnering opportunities available:
For Partnering/Licensing/ Co-development:
1. Seeking Co-development Partner/Investor/EPO supplier for Phase 3 stage Erythropoietin (EPO) patented asset for Resuscitation from Sudden Cardiac Arrest (A groundbreaking approach). By using the 351(A) dossier, an easy and quick path via 351 (K) Biosimilar approval for multiple indications may be obtained.
2. Seeking Licensing/Partnering: Phase 2 Drug poised to revolutionize antiviral treatment; could be a single drug to treat all the "tripledemic" viruses (RSV, FLU, COVID). Also, Phase 2 trials are starting in Central Africa for MPOX. Very effective in Bird Flu and Measles too.
3. Seeking Co-development/Out-Licensing: Phase 3 stage small molecule eye drop to treat pre-surgical cataract (typically patients under 72 years of age).
4. Seeking Acquisition /JV – Clinical stage Drug preventing Myelodysplastic Syndromes (MDS) from advancing to full-scale myelogenous Leukemia [Second Human Trial (n=30) ongoing in AU]. Now Leveraging latest in AI.
For Acquisition:
1. Lucrative Opportunity to acquire IP Portfolio (bankruptcy disposition) of clinical stage First-in-Class Non-Opioid Analgesic.
2. Available at a very reasonable price Mountain View Pharma (MVP) including its PharmaPEG® technology, product candidates, data package of ~20 drug candidates, IP etc.- for Next-generation biologics.
3. Asset sale - US client’s Smart Drug preventing Myelodysplastic Syndromes (MDS) from advancing to full-scale myelogenous Leukemia (Second Human Trial of 30 patients ongoing in AU). Now Leveraging the Latest in AI.
Seeking Investment:
1. High ROI Opportunity to Invest within May 2025 in U.S.based medtech revolutionizing medical imaging with the world’s first portable, single-sided MRI platform (On the market). With over US $60 Million raised, our client is offering special terms to invest in current B-4/B-5 round. Expected ROI is 2-4x in 12-18 months via an IPO, strategic M&A, or private equity buyout months with an exit.
Specialized Services
1. Oligonucleotide and peptides specialist Japanese CDMO for one stop solution to accelerate R&D. 40+ PhDs, Best in quality, excellent customer service and reasonable cost.
Hope you found the content useful. We welcome your feedback and queries.